ScripAstraZeneca already considers China one of its most important markets and is increasing its focus there, announcing a $2.5bn research and development investment in Beijing along with three partnership
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C
Pink SheetThe US Food and Drug Administration leveraged safety information from two other same-in-class drugs in its review of Akebia Therapeutics, Inc. ’s Vafseo (vadadustat) for chronic kidney disease patien
ScripIdiopathic pulmonary fibrosis (IPF) has proved to be a tough disease to crack, as last year’s trial failures from Galecto Inc. and FibroGen, Inc. have shown. But Boehringer Ingelheim GmbH has de